Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

T1SIA Type 1 Diabetes Simulator with Adjunctive therapies - GLP1

Coordinator
Universitat Politecnica De Valencia, Spain
Runs
12 January 2026 to 11 January 2028
Status
Running
EU funding
€243k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101205486

What the project is doing

In the project's own words, from its summary on CORDIS.

People with type 1 diabetes (T1D) live with the burden of self-managing their glucose levels. Although automatic insulin delivery (AID) systems have alleviated this load, patients still need to count carbohydrates and administer insulin boluses at mealtimes, making the systems prone to human errors, which could have severe health consequences. Adjunctive therapies such as GLP-1 receptor agonists aim to mitigate these risks by reducing the impact of meals on the glucose rate of appearance in blood.

These drugs are prescribed for type 2 diabetes, but they are currently being considered for their use in T1D. Simulators are one of the essential tools for developing AID systems and the foundation for digital twins, allowing testing and validating control algorithms while avoiding any risks for the patients. However, no T1D simulator includes descriptions of GLP-1 effects. The T1SIA project will develop a T1D simulator that includes a mathematical model of GLP-1 receptor agonists’ dynamics.

This 2-year project will rely on the experience of the University of Bern and the Polytechnic University of Valencia. The first year at Bern will focus on developing a GLP-1 mathematical model, supervised by an expert in AID systems and a clinician expert in adjunctive therapies. In the second year at Valencia, the model will be integrated into a T1D simulator alongside a cohort of virtual patients under the supervision of an expert in diabetes technology.

T1SIA will allow exploring the contributions of these novel therapy drugs for research and product-development purposes in the AID and pharmaceutical industry. This project will push the candidate’s professional development, both for academic and industry positions, improving her knowledge of mathematical modeling, human physiology, and identifiability processes while also providing the candidate with skills in project management, networking, teaching and supervision, and communication.

Topics

Who is involved

OrganisationCityCountryRole
Universitat Politecnica De ValenciaValenciaSpainCoordinator
Universitaet BernBernSwitzerlandAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI